Published in Biochem Pharmacol on March 15, 2001
Adenosine receptors as therapeutic targets. Nat Rev Drug Discov (2006) 6.15
The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol (2013) 5.74
Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med (2003) 3.71
Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. J Pharmacol Exp Ther (2005) 2.03
Adenosine closes the K+ channel KCa3.1 in human lung mast cells and inhibits their migration via the adenosine A2A receptor. Eur J Immunol (2007) 1.04
Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line. Br J Pharmacol (2001) 0.96
Xanthines as adenosine receptor antagonists. Handb Exp Pharmacol (2011) 0.96
Characterization of the A2B adenosine receptor from mouse, rabbit, and dog. J Pharmacol Exp Ther (2009) 0.94
Afferent arteriolar vasodilator effect of adenosine predominantly involves adenosine A2B receptor activation. Am J Physiol Renal Physiol (2010) 0.91
In vivo hypoxic preconditioning protects from warm liver ischemia-reperfusion injury through the adenosine A2B receptor. Transplantation (2012) 0.90
Evidence for an intracellular localization of the adenosine A2B receptor in rat cardiomyocytes. Basic Res Cardiol (2011) 0.90
Comparison of three different A1 adenosine receptor antagonists on infarct size and multiple cycle ischemic preconditioning in anesthetized dogs. J Pharmacol Exp Ther (2003) 0.89
The role of mechanical forces and adenosine in the regulation of intestinal enterochromaffin cell serotonin secretion. Am J Physiol Gastrointest Liver Physiol (2011) 0.88
Dynamic purine signaling and metabolism during neutrophil-endothelial interactions. Purinergic Signal (2005) 0.88
B-Myb regulates the A(2B) adenosine receptor in vascular smooth muscle cells. J Cell Biochem (2008) 0.86
Recent improvements in the development of A(2B) adenosine receptor agonists. Purinergic Signal (2008) 0.86
Selective inhibition of KCa3.1 channels mediates adenosine regulation of the motility of human T cells. J Immunol (2013) 0.84
Recent improvements in the development of A(2B) adenosine receptor agonists. Purinergic Signal (2009) 0.84
Characterization of human and rodent native and recombinant adenosine A(2B) receptors by radioligand binding studies. Purinergic Signal (2006) 0.82
A2B adenosine receptors inhibit superoxide production from mitochondrial complex I in rabbit cardiomyocytes via a mechanism sensitive to Pertussis toxin. Br J Pharmacol (2011) 0.82
Comparison of human recombinant adenosine A2B receptor function assessed by Fluo-3-AM fluorometry and microphysiometry. Br J Pharmacol (2003) 0.80
Adenosine A₂A and A₂B receptors are both required for adenosine A₁ receptor-mediated cardioprotection. Am J Physiol Heart Circ Physiol (2011) 0.79
Opposite effects of uracil and adenine nucleotides on the survival of murine cardiomyocytes. J Cell Mol Med (2008) 0.78
IFN-γ Prevents Adenosine Receptor (A2bR) Upregulation To Sustain the Macrophage Activation Response. J Immunol (2015) 0.78
Adenosine A2B receptors induce proliferation, invasion and activation of cAMP response element binding protein (CREB) in trophoblast cells. BMC Pregnancy Childbirth (2014) 0.78
Probing biased/partial agonism at the G protein-coupled A(2B) adenosine receptor. Biochem Pharmacol (2014) 0.78
Novel selective antagonist radioligands for the pharmacological study of A(2B) adenosine receptors. Purinergic Signal (2006) 0.78
Contribution of epoxyeicosatrienoic acids to the cerebral blood flow response to hypoxemia. J Appl Physiol (1985) (2015) 0.78
The impact of commercially available purinergic ligands on purinergic signalling research. Purinergic Signal (2011) 0.75
International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev (2001) 9.90
Nomenclature and classification of purinoceptors. Pharmacol Rev (1994) 5.32
Direct observation of brownian motion of lipids in a membrane. Proc Natl Acad Sci U S A (1991) 3.91
Diffusion of injected macromolecules within the cytoplasm of living cells. Proc Natl Acad Sci U S A (1981) 3.61
The biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice with a disruption of the gene for stearoyl-CoA desaturase 1. J Biol Chem (2000) 2.97
125I-4-aminobenzyl-5'-N-methylcarboxamidoadenosine, a high affinity radioligand for the rat A3 adenosine receptor. Mol Pharmacol (1994) 2.65
Functionalized congeners of 1,3-dialkylxanthines: preparation of analogues with high affinity for adenosine receptors. J Med Chem (1985) 2.52
Structural mosaicism on the submicron scale in the plasma membrane. Biophys J (1998) 2.50
The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol (2013) 2.48
Unconfined lateral diffusion and an estimate of pericellular matrix viscosity revealed by measuring the mobility of gold-tagged lipids. J Cell Biol (1993) 2.47
Adenosine A3 receptor stimulation and cerebral ischemia. Eur J Pharmacol (1994) 2.33
The cardiac effects of adenosine. Prog Cardiovasc Dis (1989) 2.20
Spatial Fourier analysis of video photobleaching measurements. Principles and optimization. Biophys J (1991) 2.13
Functionalized congeners of adenosine: preparation of analogues with high affinity for A1-adenosine receptors. J Med Chem (1985) 2.12
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors. J Med Chem (1994) 2.10
Towards a revised nomenclature for P1 and P2 receptors. Trends Pharmacol Sci (1997) 2.09
Molecular cloning and characterization of the human A3 adenosine receptor. Proc Natl Acad Sci U S A (1993) 2.08
Risk factors for epistaxis during nasotracheal intubation. Anaesth Intensive Care (2002) 2.04
A lipogenic diet in mice with a disruption of the stearoyl-CoA desaturase 1 gene reveals a stringent requirement of endogenous monounsaturated fatty acids for triglyceride synthesis. J Lipid Res (2001) 2.03
Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor. J Biol Chem (1995) 1.92
Enzyme inhibition by acetylenic compounds. Biochem Biophys Res Commun (1970) 1.90
A binding site model and structure-activity relationships for the rat A3 adenosine receptor. Mol Pharmacol (1994) 1.87
Pharmacological characterization of novel A3 adenosine receptor-selective antagonists. Neuropharmacology (1997) 1.86
Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y(1) receptor ligands. J Med Chem (2000) 1.85
[3H]xanthine amine congener of 1,3-dipropyl-8-phenylxanthine: an antagonist radioligand for adenosine receptors. Proc Natl Acad Sci U S A (1986) 1.85
Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate. J Med Chem (1993) 1.84
Competitive and selective antagonism of P2Y1 receptors by N6-methyl 2'-deoxyadenosine 3',5'-bisphosphate. Br J Pharmacol (1998) 1.80
Lymphocyte subset reference ranges in adult Caucasians. Clin Immunol Immunopathol (1991) 1.79
Differential effects of P2-purinoceptor antagonists on phospholipase C- and adenylyl cyclase-coupled P2Y-purinoceptors. Br J Pharmacol (1994) 1.77
Canine mast cell adenosine receptors: cloning and expression of the A3 receptor and evidence that degranulation is mediated by the A2B receptor. Mol Pharmacol (1997) 1.74
A(2A) adenosine receptor-mediated inhibition of renal injury and neutrophil adhesion. Am J Physiol Renal Physiol (2000) 1.71
Role of the extracellular loops of G protein-coupled receptors in ligand recognition: a molecular modeling study of the human P2Y1 receptor. Biochemistry (1999) 1.64
A mutational analysis of residues essential for ligand recognition at the human P2Y1 receptor. Mol Pharmacol (1997) 1.63
A physiological role of the adenosine A3 receptor: sustained cardioprotection. Proc Natl Acad Sci U S A (1998) 1.63
Adenosine A1 and A2 receptors: structure--function relationships. Med Res Rev (1992) 1.62
Deoxyadenosine bisphosphate derivatives as potent antagonists at P2Y1 receptors. J Med Chem (1998) 1.61
Selective A2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney. Am J Physiol (1999) 1.61
Human P2Y1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. J Med Chem (1998) 1.61
Inhibition of prostaglandin biosynthesis by eicosa-5,8,11,14-tetraynoic acid. Biochim Biophys Acta (1970) 1.59
A2A adenosine receptors from rat striatum and rat pheochromocytoma PC12 cells: characterization with radioligand binding and by activation of adenylate cyclase. Mol Pharmacol (1992) 1.57
Direct preconditioning of cultured chick ventricular myocytes. Novel functions of cardiac adenosine A2a and A3 receptors. J Clin Invest (1996) 1.57
Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system. J Comp Neurol (1998) 1.55
A functionalized congener approach to adenosine receptor antagonists: amino acid conjugates of 1,3-dipropylxanthine. Mol Pharmacol (1986) 1.55
Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition. Mol Pharmacol (1996) 1.54
The role of amino acids in extracellular loops of the human P2Y1 receptor in surface expression and activation processes. J Biol Chem (1999) 1.54
Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A(2A) receptor agonists. Br J Pharmacol (2001) 1.53
Probing the adenosine receptor with adenosine and xanthine biotin conjugates. FEBS Lett (1985) 1.52
Patterns of A2A extracellular adenosine receptor expression in different functional subsets of human peripheral T cells. Flow cytometry studies with anti-A2A receptor monoclonal antibodies. Mol Pharmacol (1999) 1.51
Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors. J Med Chem (1997) 1.51
Direct measurement of lateral transport in membranes by using time-resolved spatial photometry. Proc Natl Acad Sci U S A (1985) 1.51
Identification of the A2 adenosine receptor binding subunit by photoaffinity crosslinking. Proc Natl Acad Sci U S A (1989) 1.50
Gene dose effect reveals no Gs-coupled A2A adenosine receptor reserve in murine T-lymphocytes: studies of cells from A2A-receptor-gene-deficient mice. Biochem J (2001) 1.49
Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation. J Clin Invest (1997) 1.47
Molecular probes for extracellular adenosine receptors. Biochem Pharmacol (1987) 1.47
Apparent affinity of some 8-phenyl-substituted xanthines at adenosine receptors in guinea-pig aorta and atria. Br J Pharmacol (1987) 1.45
Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. J Med Chem (2000) 1.44
Distinct pathways of desensitization of A1- and A2-adenosine receptors in DDT1 MF-2 cells. Mol Pharmacol (1991) 1.42
A new high affinity, iodinated adenosine receptor antagonist as a radioligand/photoaffinity crosslinking probe. Mol Pharmacol (1987) 1.42
Species differences in structure-activity relationships of adenosine agonists and xanthine antagonists at brain A1 adenosine receptors. FEBS Lett (1986) 1.42
Transgenic A1 adenosine receptor overexpression increases myocardial resistance to ischemia. Proc Natl Acad Sci U S A (1997) 1.41
Hepatoprotective activity of scopoletin, a constituent of Solanum lyratum. Arch Pharm Res (1998) 1.40
G protein-dependent activation of phospholipase C by adenosine A3 receptors in rat brain. Mol Pharmacol (1995) 1.40
A2B adenosine and P2Y2 receptors stimulate mitogen-activated protein kinase in human embryonic kidney-293 cells. cross-talk between cyclic AMP and protein kinase c pathways. J Biol Chem (1999) 1.38
Blockade of adenosine A2B receptors ameliorates murine colitis. Br J Pharmacol (2008) 1.35
Induction of cortical oscillations in spreading cells by depolymerization of microtubules. Cell Motil Cytoskeleton (2001) 1.35
Modelling the P2Y purinoceptor using rhodopsin as template. Drug Des Discov (1995) 1.35
Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia. Haemophilia (2001) 1.33
Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition. Mol Pharmacol (1996) 1.33
Cloning, expression, and characterization of the unique bovine A1 adenosine receptor. Studies on the ligand binding site by site-directed mutagenesis. J Biol Chem (1992) 1.32
Acyclic and cyclopropyl analogues of adenosine bisphosphate antagonists of the P2Y1 receptor: structure-activity relationships and receptor docking. J Med Chem (2001) 1.32
The A2 adenosine receptor: guanine nucleotide modulation of agonist binding is enhanced by proteolysis. Mol Pharmacol (1991) 1.32
Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem (1998) 1.32
Behavioral effects of A1- and A2-selective adenosine agonists and antagonists: evidence for synergism and antagonism. J Pharmacol Exp Ther (1991) 1.31
Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes. J Med Chem (1998) 1.31
Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype. J Med Chem (1996) 1.31
The role of inflammation in vascular diseases. J Leukoc Biol (2000) 1.30
Activation of hippocampal adenosine A3 receptors produces a desensitization of A1 receptor-mediated responses in rat hippocampus. J Neurosci (1997) 1.29
Identification of potent P2Y-purinoceptor agonists that are derivatives of adenosine 5'-monophosphate. Br J Pharmacol (1996) 1.27
A novel cardioprotective function of adenosine A1 and A3 receptors during prolonged simulated ischemia. Am J Physiol (1997) 1.27
Ring-Constrained (N)-methanocarba nucleosides as adenosine receptor agonists: independent 5'-uronamide and 2'-deoxy modifications. Bioorg Med Chem Lett (2001) 1.26
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors. J Med Chem (1995) 1.26
Structure-activity relationships of bisphosphate nucleotide derivatives as P2Y1 receptor antagonists and partial agonists. J Med Chem (1999) 1.25
Molecular modeling of adenosine receptors. I. The ligand binding site on the A1 receptor. Drug Des Discov (1992) 1.25
Subdural metastases from prostatic adenocarcinoma. Surg Neurol (1981) 1.24
Induction of apoptosis in HL-60 human promyelocytic leukemia cells by adenosine A(3) receptor agonists. Biochem Biophys Res Commun (1996) 1.23
Antagonists of the receptor-G protein interface block Gi-coupled signal transduction. J Biol Chem (1998) 1.22
Arachidonoyl ethanolamide-[1,2-14C] as a substrate for anandamide amidase. Life Sci (1995) 1.21
Adenosine A(2A) receptor stimulation reduces inflammation and neointimal growth in a murine carotid ligation model. Arterioscler Thromb Vasc Biol (2001) 1.21
Use of the triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors. Drug Des Discov (1999) 1.21
Enhanced protection from renal ischemia-reperfusion [correction of ischemia:reperfusion] injury with A(2A)-adenosine receptor activation and PDE 4 inhibition. Kidney Int (2001) 1.20
Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J Comp Neurol (2001) 1.20
Conjugates of catecholamines. 1. N-alkyl-functionalized carboxylic acid congeners and amides related to isoproterenol. J Med Chem (1983) 1.20
A mouse model for vitiligo. J Invest Dermatol (1986) 1.19
Allosteric modulation of A(3) adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives. Mol Pharmacol (2001) 1.18
Studies on the mechanism of polyethylene glycol-mediated cell fusion using fluorescent membrane and cytoplasmic probes. J Cell Biol (1983) 1.18